Department of Biochemistry and Molecular Biology, Medical University of Lublin, 1 Chodzki Street, 20-093 Lublin, Poland.
Int J Mol Sci. 2024 Oct 12;25(20):10982. doi: 10.3390/ijms252010982.
Cancer is a multifactorial disease resulting from both genetic factors and epigenetic changes. Histone acetylation, a post-translational modification, which alters chromatin architecture and regulates gene expression is associated with cancer initiation, development and progression. Aberrations in global histone acetylation levels are observed in various cancer cells and are also associated with patients' tumor aggressiveness. Therefore, histone acetylation may have prognostic utility and serve as a potential biomarker of cancer progression and patients' prognosis. The reversible modification of histones by an acetyl group is versatile. One particular histone can be acetylated on different lysine residues, subsequently resulting in different biological outcomes. Here, we discuss recent findings on the acetylation of the highly conserved histone protein H3 in the context of cancer biology. Specifically, we review the acetylation of particular H3 residues in various cancer types. We further highlight the significance of H3 acetylation levels as a potential cancer biomarker with prognostic implications.
癌症是一种多因素疾病,源自遗传因素和表观遗传改变。组蛋白乙酰化是一种翻译后修饰,可改变染色质结构并调节基因表达,与癌症的发生、发展和进展有关。在各种癌细胞中观察到整体组蛋白乙酰化水平的异常,并且与患者的肿瘤侵袭性相关。因此,组蛋白乙酰化可能具有预后效用,并可作为癌症进展和患者预后的潜在生物标志物。组蛋白通过乙酰基的可逆修饰具有多功能性。一个特定的组蛋白可以在不同的赖氨酸残基上被乙酰化,随后导致不同的生物学结果。在这里,我们讨论了在癌症生物学背景下高度保守的组蛋白 H3 乙酰化的最新发现。具体来说,我们综述了各种癌症类型中特定 H3 残基的乙酰化。我们进一步强调了 H3 乙酰化水平作为具有预后意义的潜在癌症生物标志物的重要性。